1350736-07-0

Basic information

• Product Name: C₁₃H₁₅N₅O₄
• CAS NO: 1350736-07-0
• Molecular Weight: 305.293
• Mol File: 1350736-07-0.mol

Chemical Properties

• CAS DataBase Reference: C₁₃H₁₅N₅O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₃H₁₅N₅O₄(1350736-07-0)
• EPA Substance Registry System: C₁₃H₁₅N₅O₄(1350736-07-0)

Safety Data

• Hazardous Substances Data: 1350736-07-0(Hazardous Substances Data)

Upstream product

• 1272971-35-3 2′,3′,5′-O-tribenzyl-1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 1191237-48-5 C₃₄H₃₃N₅O₄ 
• 1191237-40-7 C₇H₁₄O₅ 
• 917567-08-9 (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxolan-2-one 
• 1191237-41-8 C₂₈H₃₂O₅ 
• 1314972-33-2 (3R,4R,5R)-3,4-bis(benzyloxy)-5-(benzyloxymethyl)-3-methyl-tetrahydro-furan-2-ol 

Relevant articles and documents

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.

1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT

Provided are prodrugs of pyrrolo[l,2-f][l,2,4]triazin-7-yl nucleoside phosphates wherein the 1 '' position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.